Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections
Status:
Completed
Trial end date:
2019-10-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether AB103 is safe and effective in the
treatment of patients with necrotizing soft tissue infections (NSTI) receiving standard of
care therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Atox Bio Ltd
Collaborator:
Biomedical Advanced Research and Development Authority